Today: 15 May 2026
Browse Category

NASDAQ:HCWB 15 May 2026

HCW Biologics Stock News: Profit, Pipeline and Nasdaq Risk Put HCWB Back in Focus

HCW Biologics Stock News: Profit, Pipeline and Nasdaq Risk Put HCWB Back in Focus

HCW Biologics posted first-quarter net income of $3.47 million on $6.54 million in revenue, reversing a year-earlier loss, after a licensing deal with Beijing-based Trimmune Biotech. The company remains below Nasdaq’s $1 minimum bid and awaits early human data from its lead autoimmune drug, HCW9302, in alopecia areata. HCW also reported positive animal study results for a lung drug targeting premature infants.
15 May 2026

Stock Market Today

  • Key Advice for Investors: Focus on Long-Term Market Investment, Not Short-Term Fluctuations
    May 15, 2026, 6:19 AM EDT. The stock market has confounded many investors with strong returns despite economic challenges, including inflation and geopolitical tensions. The S&P 500 gained about 33% in the past year, the Dow rose roughly 23%, and the Nasdaq surged 47%. Experts caution against trying to predict short-term movements, which are highly volatile and influenced by unpredictable factors like trade tensions and supply disruptions. Historically, holding an investment such as an S&P 500 fund for longer periods significantly reduces the risk of losses. Short-term trading can result in locked-in losses and missed recovery gains, as illustrated by hypothetical scenarios involving the Vanguard S&P 500 ETF (VOO). Data shows one-year periods see negative returns 33% of the time, but this risk declines sharply over five- and ten-year horizons. Investors are advised to prioritize time in the market over timing it to enhance potential returns.

Latest articles

HCW Biologics Stock News: Profit, Pipeline and Nasdaq Risk Put HCWB Back in Focus

HCW Biologics Stock News: Profit, Pipeline and Nasdaq Risk Put HCWB Back in Focus

15 May 2026
HCW Biologics posted first-quarter net income of $3.47 million on $6.54 million in revenue, reversing a year-earlier loss, after a licensing deal with Beijing-based Trimmune Biotech. The company remains below Nasdaq’s $1 minimum bid and awaits early human data from its lead autoimmune drug, HCW9302, in alopecia areata. HCW also reported positive animal study results for a lung drug targeting premature infants.
MicroAlgo Stock Jumps Before The Bell As Quantum Circuit Algorithm Puts MLGO Back In Play

MicroAlgo Stock Jumps Before The Bell As Quantum Circuit Algorithm Puts MLGO Back In Play

15 May 2026
MicroAlgo Inc. announced a new algorithm for automating quantum circuit design, sending its shares up 13.18% to $4.55 at Thursday’s close and 20.88% higher in pre-market trading Friday. The company said its tool can generate and evaluate quantum circuits without pre-set specs and tested it on standard problems, but did not disclose customers, pricing, or a launch date.
Datavault AI Stock Rises Before Q1 Results as Crypto Bill Vote Puts DVLT Back in Focus

Datavault AI Stock Rises Before Q1 Results as Crypto Bill Vote Puts DVLT Back in Focus

15 May 2026
Datavault AI shares climbed about 10% in early premarket trading ahead of its first-quarter results and webcast. The move follows a Senate committee vote advancing a crypto-market bill tied to Datavault’s tokenization strategy. The company recently raised $60 million in a stock sale to fund its GPU edge-network plan, raising dilution concerns. Shares were quoted at $0.5861, up from $0.55 in the recent offering.
Go toTop